drugset / Trial / NCT00376688

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00376688

Phase 2 Completed 31 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2006-07-11
Primary completion
2008-06-12
Completion
2019-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule 25 mg Intravenous

Indications